Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen

    ... serious adverse event that occurred among 85 AML and myelodysplastic syndromes (MDS) patients treated in a prospective clinical study using ...

    Research Article last updated 11/08/2017 - 9:26am.

  2. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... Patients with lower-risk myelodysplastic syndromes (MDS) are mainly affected by chronic anemia and fatigue. ...

    Research Article last updated 10/23/2017 - 11:08am.

  3. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes

    ... Myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell disorders associated ...

    Research Article last updated 11/03/2017 - 10:36am.

  4. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell ...

    Research Article last updated 10/23/2017 - 11:00am.

  5. SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes

    ... Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms ...

    Research Article last updated 10/20/2017 - 9:14am.

  6. Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times

    ... measures captured by patient-reported outcomes (PROs). Myelodysplastic and myelodysplastic/myeloproliferative (MDS/MPN) neoplasm overlap syndromes are notable for significant morbidity and mortality, including a wide ...

    Research Article last updated 09/13/2017 - 8:29am.

  7. Increasing the effectiveness of hematopoiesis in myelodysplastic syndromes: erythropoiesis-stimulating agents and transforming growth factor-β superfamily inhibitors

    ... Patients with lower-risk myelodysplastic syndromes (MDS) are mainly affected by chronic anemia and fatigue. ...

    Research Article last updated 10/02/2017 - 10:10am.

  8. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity

    ... Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal hematopoietic stem cell ...

    Research Article last updated 10/02/2017 - 10:03am.

  9. Computational Modeling and Treatment Identification in the Myelodysplastic Syndromes

    ... review discusses the need for computational modeling in myelodysplastic syndromes (MDS) and early test results. RECENT FINDINGS: As our ...

    Research Article last updated 09/18/2017 - 9:46am.

  10. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... BACKGROUND: Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept ...

    Research Article last updated 09/18/2017 - 1:38pm.